Format

Send to

Choose Destination
Nat Med. 2018 Aug;24(8):1097-1103. doi: 10.1038/s41591-018-0145-0. Epub 2018 Aug 6.

Learning from bacterial competition in the host to develop antimicrobials.

Raffatellu M1,2,3,4.

Author information

1
Department of Microbiology and Molecular Genetics, University of California Irvine, Irvine, CA, USA. manuelar@ucsd.edu.
2
Division of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA. manuelar@ucsd.edu.
3
Chiba University-University of California San Diego Center for Mucosal Immunology, Allergy, and Vaccines (CU-UCSD cMAV), La Jolla, CA, USA. manuelar@ucsd.edu.
4
Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA. manuelar@ucsd.edu.

Abstract

In recent years, the alarming increase of antibiotic resistance, compounded by the simultaneous decrease in development of new antibiotics, has created serious concerns for public health. Moreover, current antibiotics also target the beneficial commensal microbes (microbiota) that inhabit our body, sometimes with significant health consequences. The answer to the antibiotic crisis thus involves broad, creative efforts to develop new treatments for infectious agents. Here I discuss what can be learned from investigating microbial competition in vivo and how this knowledge can be utilized to devise new narrow-spectrum therapeutics that target bacterial pathogens while minimizing deleterious effects to the microbiota.

PMID:
30082869
DOI:
10.1038/s41591-018-0145-0

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center